do insurance companies cover glp-1 drugs Ole Miss researchers study barriers to coverage Insurance and GLP-1s: How to

Compared with other CVOTs involving GLP-1RA, participants in the AMPLITUDE-O trial had the longest duration of diabetes (15 years), lowest mean eGFR (72 ml/min/1.73 m 2 ) with a higher percentage (32%) of people with renal disease (eGFR 2560 mL/min), highest glycosilated hemoglobin (8.9%), and highest percentage of insulin use (62%) or sodiumglucose transporter-2 inhibitors (SGLT-2i) (15%) at baseline, thus identifying a more fragile population

293 (2), E604E609 (2007)

doi:10.1016/j.jaut.2015.07.009 Frhlich E, Wahl R

Understanding these behavioral dynamics is critical for pharmaceutical stakeholders assessing market retention, pricing strategies, and patient engagement models in the evolving GLP-1 landscape

Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease

Recent studies have focused on oxidative stress as the underlying cause of metal-based NP toxicity